<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935855</url>
  </required_header>
  <id_info>
    <org_study_id>20150003862</org_study_id>
    <nct_id>NCT02935855</nct_id>
  </id_info>
  <brief_title>ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)</brief_title>
  <acronym>ORGANON</acronym>
  <official_title>Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic and nondiabetic patients will be evaluated if they had a first diagnosis of
      non-valvular atrial fibrillation and in therapy with non-vitamin K oral anticoagulants and
      with vitamin K oral anticoagulants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parameters evaluated:

        -  anthropometric indices

        -  glycated haemoglobin, basal and postprandial glycemia

        -  lipid profile

        -  small and dense LDL; oxidized LDL

        -  I troponin

        -  red and white cells count; platelets count

        -  creatinin, transaminases, iron

        -  fibrinogen, D-dimer, anti-thrombin III

        -  Hs-CRP, metalloproteinases 2 and 9

        -  incidence of bleeding
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy on coagulation parameters</measure>
    <time_frame>12 months</time_frame>
    <description>Red cells count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy on coagulation parameters</measure>
    <time_frame>12 months</time_frame>
    <description>Platelets count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy on coagulation parameters</measure>
    <time_frame>12 months</time_frame>
    <description>fibrinogen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy on coagulation parameters</measure>
    <time_frame>12 months</time_frame>
    <description>D-dimer, anti-thrombin III</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding risk</measure>
    <time_frame>12 months</time_frame>
    <description>HAS-BLED score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation parameters</measure>
    <time_frame>12 months</time_frame>
    <description>Hs-CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation parameters</measure>
    <time_frame>12 months</time_frame>
    <description>White cells count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial damage</measure>
    <time_frame>12 months</time_frame>
    <description>Metalloproteinases 2 and 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative status</measure>
    <time_frame>12 months</time_frame>
    <description>Small and dense LDL; oxidized LDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart damage</measure>
    <time_frame>12 months</time_frame>
    <description>I troponin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability parameters</measure>
    <time_frame>12 months</time_frame>
    <description>Serum creatinin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability parameters</measure>
    <time_frame>12 months</time_frame>
    <description>Serum transaminases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability parameters</measure>
    <time_frame>12 months</time_frame>
    <description>Plasma iron</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Nondiabetics (group 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetics (group 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nondiabetics (group 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetics (group 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <arm_group_label>Nondiabetics (group 1)</arm_group_label>
    <arm_group_label>Diabetics (group 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <arm_group_label>Nondiabetics (group 1)</arm_group_label>
    <arm_group_label>Diabetics (group 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <arm_group_label>Nondiabetics (group 1)</arm_group_label>
    <arm_group_label>Diabetics (group 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <arm_group_label>Nondiabetics (group 1)</arm_group_label>
    <arm_group_label>Diabetics (group 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <arm_group_label>Nondiabetics (group 2)</arm_group_label>
    <arm_group_label>Diabetics (group 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acenocumarole</intervention_name>
    <arm_group_label>Nondiabetics (group 2)</arm_group_label>
    <arm_group_label>Diabetics (group 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-valvular atrial fibrillation

          -  nondiabetic patients

          -  type 1 and 2 diabetic patients

        Exclusion Criteria:

          -  patients with cancer

          -  patients with chronic inflammation diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Derosa, MD, PhD, FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pavia and IRCCS Policlinico San Matteo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giuseppe Derosa, MD, PhD, FESC</last_name>
    <phone>+39 0382 50 2614</phone>
    <email>giuseppe.derosa@unipv.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Derosa, MD, PhD, FESC</last_name>
      <phone>+39 0382 502614</phone>
      <email>giuseppe.derosa@unipv.it</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Maffioli, MD</last_name>
      <email>pamelamaffioli@hotmail.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giuseppe Derosa, MD, PhD, FESC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pamela Maffioli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>October 17, 2016</last_update_submitted>
  <last_update_submitted_qc>October 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pavia</investigator_affiliation>
    <investigator_full_name>Giuseppe Derosa</investigator_full_name>
    <investigator_title>MD, PhD, FESC</investigator_title>
  </responsible_party>
  <keyword>Diabetic patients</keyword>
  <keyword>nondiabetic patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

